Patents by Inventor Luis Bermudez-Humaran

Luis Bermudez-Humaran has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • strains for treating and preventing gastrointestinal pain
    Patent number: 11717543
    Abstract: The present invention relates to a bacterial strain of the Faecalibacterium prausnitzii species selected from a bacterial strain belonging to one of the phylogroups I, II and III, for use in the treatment and/or prevention of visceral abdominal pain in an individual. The present invention also concerns compositions comprising said bacterial strains as well as specific strains as such.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: August 8, 2023
    Assignees: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6), ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, ECOLE D'INGENIEURS DE PURPAN
    Inventors: Philippe Langella, Sylvie Miquel, Rebeca Martin Rosique, Luis Bermudez Humaran, Muriel Thomas, Harry Sokol, Frédéric Carvalho, Vassilia Theodorou
  • Use of E. coli strains expressing high level of alpha-Gal to modulate immunity and provide protection against infectious diseases in animals
    Publication number: 20230232882
    Abstract: The present invention concerns an E. coli strains expressing high level of ?-Gal, in particular selected in the group consisting of E. coli Nissle 1917 strain, E. coli O111 strain, E. coli O86:B7 strain, and mixture thereof, as a probiotic and/or feed additive and/or oral vaccine in a non-human animal, in particular fish and poultry, to prevent and/or reduce an infectious disease caused by a pathogen expressing ?-Gal on its surface.
    Type: Application
    Filed: June 3, 2021
    Publication date: July 27, 2023
    Inventors: Alejandro CABEZAS-CRUZ, Lourdes MATEOS-HERNANDEZ, Astrid Sibylle HOLZER, Luis BERMUDEZ-HUMARAN, Veronica RISCO-CASTILLO, Jose de Jesus DE LA FUENTE-GARCIA, Edgar TORRES-MARAVILLA, Jacques GUILLOT
  • Probiotic strain of
    Patent number: 11471498
    Abstract: The present disclosure relates to a new probiotic strain of Lactobacillus brevis, isolated from pulque and exhibiting anti-cancer properties, as well as to compositions which contain said strain.
    Type: Grant
    Filed: June 5, 2019
    Date of Patent: October 18, 2022
    Assignees: INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT, INSTITUTO POLITECNICO NACIONAL (IPN)
    Inventors: Luis Bermudez Humaran, Edgar Torres Maravilla, Philippe Langella, Maria Elena Sanchez-Pardo
  • NEW PROBIOTIC STRAIN OF LACTOBACILLUS BREVIS
    Publication number: 20210268044
    Abstract: The present invention disclosure relates to a new probiotic strain of Lactobacillus brevis, isolated from pique and exhibiting anti-cancer properties, as welt as to compositions which contain said strain.
    Type: Application
    Filed: June 5, 2019
    Publication date: September 2, 2021
    Applicants: INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT, INSTITUTO POLITECNICO NACIONAL (IPN)
    Inventors: Luis BERMUDEZ HUMARAN, Edgar TORRES MARAVILLA, Philippe LANGELLA, Maria Elena SANCHEZ-PARDO
  • strain CNCM 1-4573 for the treatment and prevention of gastrointestinal inflammation
    Patent number: 10918678
    Abstract: The invention relates to a bacterial strain of species Faecalibacterium prausnitzii deposited at the CNCM under access number CNCM I-4573, for use in the treatment and/or prevention of an inflammatory gastrointestinal illness in an individual.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: February 16, 2021
    Assignees: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA), SORBONNE UNIVERSITE, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS
    Inventors: Philippe Langella, Rebeca Martin Rosique, Luis Bermudez Humaran, Florian Chain, Harry Sokol
  • FAECALIBACTERIUM PRAUSNITZII STRAINS FOR TREATING AND PREVENTING GASTROINTESTINAL PAIN
    Publication number: 20200316138
    Abstract: The present invention relates to a bacterial strain of the Faecalibacterium prausnitzii species selected from a bacterial strain belonging to one of the phylogroups I, II and III, for use in the treatment and/or prevention of visceral abdominal pain in an individual. The present invention also concerns compositions comprising said bacterial strains as well as specific strains as such.
    Type: Application
    Filed: June 22, 2020
    Publication date: October 8, 2020
    Inventors: Philippe LANGELLA, Sylvie MIQUEL, Rebeca MARTIN ROSIQUE, Luis BERMUDEZ HUMARAN, Muriel THOMAS, Harry SOKOL, Frédéric CARVALHO, Vassilia THEODOROU
  • FAECALIBACTERIUM PRAUSNITZII STRAINS FOR TREATING AND PREVENTING GASTROINTESTINAL PAIN
    Publication number: 20190381115
    Abstract: The present invention relates to a bacterial strain of the Faecalibacterium prausnitzii species selected from a bacterial strain belonging to one of the phylogroups I, II and III, for use in the treatment and/or prevention of visceral abdominal pain in an individual. The present invention also concerns compositions comprising said bacterial strains as well as specific strains as such.
    Type: Application
    Filed: November 13, 2015
    Publication date: December 19, 2019
    Applicants: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6), ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (APHP), ECOLE D'INGENIEURS DE PURPAN
    Inventors: Philippe LANGELLA, Sylvie MIQUEL, Rebeca MARTIN ROSIQUE, Luis BERMUDEZ HUMARAN, Muriel THOMAS, Harry SOKOL, Frédéric CARVALHO, Vassilia THEODOROU
  • Lactococcus lactis producing TSLP or IL-25 and their uses as probiotics and therapeutics
    Patent number: 10238697
    Abstract: The present invention relates to recombinant Lactococcus lactis bacteria expressing and secreting TSLP or IL-25 or a combination thereof, and their use as probiotics or therapeutic agents, especially for use in the treatment of inflammatory diseases and disorders.
    Type: Grant
    Filed: April 12, 2016
    Date of Patent: March 26, 2019
    Assignee: ARES TRADING S.A.
    Inventors: Philippe Langella, Jean-Marc Chatel, Luis Bermudez-Humaran, Camille Aubry, Laurence Goffin, Simone Favre-Zimmerli, Yolande Chvatchko
  • FAECALIBACTERIUM PRAUSNITZII STRAIN CNCM 1-4573 FOR THE TREATMENT AND PREVENTION OF GASTROINTESTINAL INFLAMMATION
    Publication number: 20190030089
    Abstract: The invention relates to a bacterial strain of species Faecalibacterium prausnitzii deposited at the CNCM under access number CNCM I-4573, for use in the treatment and/or prevention of an inflammatory gastrointestinal illness in an individual.
    Type: Application
    Filed: January 23, 2017
    Publication date: January 31, 2019
    Applicants: Institut National De La Recherche Agronomique (INRA), Sorbonne Universite, Assistance Publique - Hopitaux de Paris
    Inventors: Philippe Langella, Rebeca Martin Rosique, Luis Bermudez Humaran, Florian Chain, Harry Sokol
  • LACTOCOCCUS LACTIS PRODUCING TSLP OR IL-25 AND THEIR USES AS PROBIOTICS AND THERAPEUTICS
    Publication number: 20180104285
    Abstract: The present invention relates to recombinant Lactococcus lactis bacteria expressing and secreting TSLP or IL-25 or a combination thereof, and their use as probiotics or therapeutic agents, especially for use in the treatment of inflammatory diseases and disorders.
    Type: Application
    Filed: April 12, 2016
    Publication date: April 19, 2018
    Inventors: PHILIPPE LANGELLA, JEAN-MARC CHATEL, LUIS BERMUDEZ-HUMARAN, CAMILLE AUBRY, LAURENCE GOFFIN, SIMONE FAVRE-ZIMMERLI, YOLANDE CHVATCHKO
  • Recombinant probiotic bacteria for the prevention and treatment of inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS)
    Patent number: 9688742
    Abstract: The present invention relates to the general field of therapy of Inflammatory Bowel Disease (IBD) and/or Irritable Bowel Syndrome (IBS). Thus, the invention relates to a molecule selected from the trappin-2 protein or an active fraction thereof, a member of the WAP family proteins or an active fraction thereof or a member of the Serpin family proteins or an active fraction thereof for the treatment of Irritable Bowel Syndrome (IBS). The invention also relates to a recombinant food-grade bacterium comprising a gene selected from a gene coding for the trappin-2 protein or an active fraction thereof, a gene coding for a member of the WAP family proteins or an active fraction thereof, or a gene coding for a member of the Serpin family proteins or an active fraction thereof.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: June 27, 2017
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA), UNIVERSITE PARIS DIDEROT—Paris 7
    Inventors: Nathalie Vergnolle, Jean-Michel Sallenave, Philippe Langella, Luis Bermudez-Humaran
  • STRESS-REGULATED PROKARYOTIC EXPRESSION CASSETTES
    Publication number: 20150139940
    Abstract: The invention relates to prokaryotic expression cassettes comprising a stress-regulated promoter, the promoter of the GroESL operon of Lactococcus lactis. Said cassettes can be used for the expression of genes of interest in gram-positive bacteria, and especially for producing and releasing a protein of interest when the bacteria are administered to an individual.
    Type: Application
    Filed: May 15, 2013
    Publication date: May 21, 2015
    Inventors: Luis Bermudez Humaran, Philippe Langella, Pascale Kharrat
  • RECOMBINANT PROBIOTIC BACTERIA FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY BOWEL DISEASE (IBD) AND IRRITABLE BOWEL SYNDROME (IBS)
    Publication number: 20150073125
    Abstract: The present invention relates to the general field of therapy of Inflammatory Bowel Disease (IBD) and/or Irritable Bowel Syndrome (IBS). Thus, the invention relates to a molecule selected from the trappin-2 protein or an active fraction thereof, a member of the WAP family proteins or an active fraction thereof or a member of the Serpin family proteins or an active fraction thereof for the treatment of Irritable Bowel Syndrome (IBS). The invention also relates to a recombinant food-grade bacterium comprising a gene selected from a gene coding for the trappin-2 protein or an active fraction thereof, a gene coding for a member of the WAP family proteins or an active fraction thereof, or a gene coding for a member of the Serpin family proteins or an active fraction thereof.
    Type: Application
    Filed: September 18, 2014
    Publication date: March 12, 2015
    Inventors: Nathalie Vergnolle, Jean-Michel Sallenave, Philippe Langella, Luis Bermudez-Humaran
  • RECOMBINANT PROBIOTIC BACTERIA FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY BOWEL DISEASE (IBD) AND IRRITABLE BOWEL SYNDROME (IBS)
    Publication number: 20130344033
    Abstract: The present invention relates to the general field of therapy of Inflammatory Bowel Disease (IBD) and/or Irritable Bowel Syndrome (IBS). Thus, the invention relates to a molecule selected from the trappin-2 protein or an active fraction thereof, a member of the WAP family proteins or an active fraction thereof or a member of the Serpin family proteins or an active fraction thereof for the treatment of Irritable Bowel Syndrome (IBS). The invention also relates to a recombinant food-grade bacterium comprising a gene selected from a gene coding for the trappin-2 protein or an active fraction thereof, a gene coding for a member of the WAP family proteins or an active fraction thereof, or a gene coding for a member of the Serpin family proteins or an active fraction thereof.
    Type: Application
    Filed: May 21, 2013
    Publication date: December 26, 2013
    Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE PARIS DIDEROT - PARIS 7, INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA)
    Inventors: Nathalie Vergnolle, Jean-Michel Sallenave, Philippe Langella, Luis Bermudez-Humaran
  • RECOMBINANT PROBIOTIC BACTERIA FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY BOWEL DISEASE (IBD) AND IRRITABLE BOWEL SYNDROME (IBS)
    Publication number: 20120195859
    Abstract: The present invention relates to the general field of therapy of Inflammatory Bowel Disease (IBD) and/or Irritable Bowel Syndrome (IBS). Thus, the invention relates to a molecule selected from the trappin-2 protein or an active fraction thereof, a member of the WAP family proteins or an active fraction thereof or a member of the Serpin family proteins or an active fraction thereof for the treatment of Irritable Bowel Syndrome (IBS). The invention also relates to a recombinant food-grade bacterium comprising a gene selected from a gene coding for the trappin-2 protein or an active fraction thereof, a gene coding for a member of the WAP family proteins or an active fraction thereof, or a gene coding for a member of the Serpin family proteins or an active fraction thereof.
    Type: Application
    Filed: January 24, 2012
    Publication date: August 2, 2012
    Inventors: Nathalie VERGNOLLE, Jean-Michel Sallenave, Philippe Langella, Luis Bermudez-Humaran